Browsing: Uveal

Clinically meaningful and statistically significant improvements in progression-free survival (PFS) were observed among patients with HLA-A*02:01–negative metastatic uveal melanoma who…

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution…

The 5-year survival data from the phase 3 IMCgp100-202 study (NCT03070392) showed the overall survival (OS) to be favorable with…

The 5-year survival rate was favorable with tebentafusp-tebn (Kimmtrak) compared with investigator’s choice of therapy (ICT) for patients with HLA-A*02:01-positive…

Darovasertib plus crizotinib (Xalkori) demonstrated a statistically significant improvement in the median progression-free survival (PFS) compared with investigator’s choice of…